

Alice Chu, BS  
 Fabian Vargas, MD  
 Maen Assali, MD  
 Nishant R. Shah, MD, MPH  
 Anthony M. Reginato, MD, PhD  
 Wen-Chih Wu, MD  
 Gaurav Choudhary, MD  
 Alan R. Morrison, MD, PhD\*  
 \*Providence VA Medical Center  
 Research (151)  
 830 Chalkstone Avenue  
 Providence, Rhode Island 02908  
 E-mail: [alan\\_morrison@brown.edu](mailto:alan_morrison@brown.edu)  
<https://doi.org/10.1016/j.jcmg.2019.10.019>

Published by Elsevier on behalf of the American College of Cardiology Foundation.

Please note: †Drs. Christensen and Yu are joint first authors. Research reported in this publication was supported by Research Project Grants R01HL139795 (to Dr. Morrison), R01HL128661 (to Dr. Choudhary), and R01HL148727 (to Dr. Choudhary) from the National Heart, Lung, and Blood Institute; Institutional Development Award P20GM103652 (to Dr. Morrison) from the National Institute of General Medical Sciences; grant T35HL094308 (to Dr. Chu) from the National Heart, Lung, and Blood Institute; Career Development Award 7IK2BX002527 (to Dr. Morrison) from the U.S. Department of Veterans Affairs Biomedical Laboratory Research and Development Program; Veterans Affairs Merit Award 101CX001892 (to Dr. Choudhary); and Agency for Healthcare Research and Quality Award 5K12HS022998 (to Dr. Shah). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

## REFERENCES

1. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia. *BMC Med* 2017;15:123.
2. Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014;160:330-8.
3. Christensen JL, Sharma E, Gorvitovskaia AY, et al. Impact of slice thickness on the predictive value of lung cancer screening computed tomography in the evaluation of coronary artery calcification. *J Am Heart Assoc* 2019;8:e010110.
4. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. *J Am Coll Cardiol* 2014;63:2889-934.

## Association Between Recreational Cannabis Use and Cardiac Structure and Function



Cannabis is one of the most widely produced and consumed recreational drugs in the world, with over 192 million global users (1). The World Health Organization has warned against the potential harmful health effects of nonmedicinal cannabis use and highlighted the need for more research assessing the link between cannabis smoking and cardiovascular disease (CVD) in adults (2). Legalization of cannabis is increasing. In the United States, recreational cannabis use is legal in 12 states and has been decriminalized in many others. Discussions on the potential public health impact are

hampered by gaps in evidence and variable quality of available data. Little or no mention of cannabis exists in CVD risk assessments or lifestyle advice guideline (3,4).

We studied the association of cannabis use with cardiac structure and function using cardiovascular magnetic resonance (CMR) parameters in the UK Biobank population study (covered by the general ethical approval for UK Biobank studies from the NHS National Research Ethics Service [16/NW/0274]).

Participants without CVD but with CMR imaging data were included (5). Self-reported cannabis use was categorized as rare/never: (no use or less than monthly use of cannabis), previous regular (weekly or daily use of cannabis up to 5 years before the interview), or current regular (weekly or daily cannabis use within 5 years of the interview). Investigators were blinded to cannabis use. CMR scanning was performed at 1.5-T (MAGNETOM Aera, Siemens, Munich, Germany) with CVI42, version 5.1.1, post-processing software (Circle Cardiovascular Imaging Inc., Calgary, Canada) and semiautomated analysis of left ventricular myocardial tagged cine images was performed with CIMTag2D, version 8.1.5 (CIM Software, Medina, Minnesota). Myocardial global circumferential strain at the mid-left ventricular level was reported in absolute values.

Analysis included 3,407 individuals (age:  $62 \pm 7$  years; 55% female), with 47 current regular, 105 previously regular, and 3,255 rare/never users. Current regular users were more likely to be younger, male, and current tobacco smokers and have greater levels of social deprivation compared with rare/never users and previous regular users. They were also less likely to be taking antihypertension medication. Regular cannabis use was associated with larger indexed left ventricular end diastolic volume ( $+5.31$  ml/m<sup>2</sup>; 95% confidence interval [CI]: 1.4 to 9.3 ml/m<sup>2</sup>;  $p = 0.008$ ), end systolic volume ( $+3.3$  ml/m<sup>2</sup>; 95% CI: 0.78 to 5.83 ml/m<sup>2</sup>;  $p = 0.010$ ), and impaired global circumferential strain ( $-0.78$ ; 95% CI:  $-1.47$  to  $-0.09$ ;  $p = 0.026$ ) compared with rare/no cannabis use, even after adjustment for potential confounders including age, sex, body mass index, systolic blood pressure, use of cholesterol medication, diabetes, smoking, and alcohol consumption (Figure 1). After multivariable adjustment, there were no differences between left ventricular myocardial mass, ejection fraction, and stroke volume or right ventricular, left atrial, and right atrial parameters. Previous cannabis users had similar parameters to rare/never users.

To the best of our knowledge, this is the first study to systematically report alterations in cardiac

**FIGURE 1** Cardiac Chamber and Function Changes With Regular Versus Rare/Never Recreational Cannabis Use (N = 3,407)

Ventricular measures		Right ventricle	Left ventricle	Atrial measures		Right atrium	Left atrium
							
<b>Morphology</b>	End diastolic volume	↑	↑* #	Maximum volume	↔	↔	↔
	End systolic volume	↑	↑* #	Minimum volume	↔	↔	↔
	Stroke volume	↑	↑				
	Mass		↑ #				
<b>Function</b>	Ejection fraction	↔	↔	Emptying fraction	↔	↔	↔
	Global circumferential strain		↓* #				

Regular cannabis use was independently associated with adverse changes in left ventricle size and subclinical dysfunction compared with rare/never cannabis use.  
 \*Changes remain significant after multivariable adjustment. #Changes remain significant after adjustment for age and sex.

structure and function associated with recreational cannabis use using CMR, the current gold standard for cardiac chamber assessment. The exact mechanisms for the observed changes are not currently known. Potential study limitations include the mainly white study population (96%); use of self-reported cannabis consumption with possible recall bias; and observational study design, whereby residual confounding cannot be fully excluded, and it is unclear whether the associations observed are due to cannabis use alone or other unmeasured confounders. Cannabis also remains illegal in the United Kingdom, creating additional barriers to reporting use.

Regular cannabis use was independently associated with adverse changes in left ventricle size and subclinical dysfunction compared with rare/never cannabis use, whereas previous regular cannabis use was not. Findings should be interpreted with caution, and further research is required to understand the potential pathophysiology, dose-response effects of cannabis use, and long-term implications of regular use on the cardiovascular system. Health care professionals and policy makers may need to advise caution on regular recreational cannabis use until such systematic research is available.

**ACKNOWLEDGEMENTS** This study was conducted with the UK Biobank resource under access

application 2964. The authors thank all participants and staff involved with planning, collection, and analysis, including core laboratory analysis of the CMR imaging data.

- Mohammed Y. Khanji, MBBCh, PhD\*
- Magnus T. Jensen, MD, PhD, MSc
- Asmaa A. Kenawy, MD
- Zahra Raisi-Estabragh, MD
- Jose M. Paiva, MSc
- Nay Aung, MD
- Kenneth Fung, MD
- Elena Lukaschuk, MSc
- Filip Zemrak, MD, PhD
- Aaron M. Lee, BSc, MD, PhD
- Ahmet Barutcu, MD
- Edd Maclean, MD
- Jackie Cooper, MSc
- Stefan K. Piechnik, MD, PhD
- Stefan Neubauer, MD, PhD
- Steffen E. Petersen, MSc, MPH, MD, PhD

\*Queen Mary University of London  
 Newham University Hospital  
 Barts Health NHS Trust  
 Glen Road  
 London E13 8SL  
 United Kingdom  
 E-mail: [m.khanji@qmul.ac.uk](mailto:m.khanji@qmul.ac.uk)  
<https://doi.org/10.1016/j.jcmg.2019.10.012>

© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please note: Drs. Petersen, Neubauer, and Piechnik acknowledge the British Heart Foundation for funding the manual analysis to create a cardiovascular magnetic resonance imaging reference standard for the UK Biobank imaging resource in 5000 cardiovascular magnetic resonance scans ([www.bhf.org.uk](http://www.bhf.org.uk); PG/14/89/31194). Dr. Aung is supported by a Wellcome Trust Research Training Fellowship ([wellcome.ac.uk](http://wellcome.ac.uk); 203553/Z/Z). Dr. Fung is supported by the Medical College of Saint Bartholomew's Hospital Trust, an independent registered charity that promotes and advances medical and dental education and research at Barts and the London School of Medicine and Dentistry. Dr. Piechnik has received support from the National Institute for Health Research (NIHR) Cardiovascular Biomedical Research Centre at Barts. Drs. Piechnik and Lee have received support from and from the "SmartHeart" Engineering and Physical Sciences Research Council (EPSRC) programme grant ([www.nihr.ac.uk](http://www.nihr.ac.uk); EP/P001009/1). Dr. Jensen is supported by The Danish Heart Foundation (16-R107-A6791) and the Danish Society of Cardiology. Drs. Neubauer and Piechnik have received support from the Oxford National Institute for Health Research Biomedical Research Centre and the Oxford British Heart Foundation Centre of Research Excellence. This project was enabled through access to the Medical Research Council (MRC) eMedLab Medical Bioinformatics infrastructure, supported by the Medical Research Council. The funders provided support in the form of salaries for authors as detailed but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Petersen provides consultancy to Circle Cardiovascular Imaging Inc., Calgary, Canada, and Servier. Dr. Jensen has served as consultant, on advisory boards, or as invited speaker for AstraZeneca, Novo Nordisk, Novartis, and GE. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

## REFERENCES

1. United Nations Office on Drugs and Crime (UNODC). Statistics and Data. Available at: [https://data.unodc.org/drugs/prevalence\\_regional](https://data.unodc.org/drugs/prevalence_regional). Accessed April 7, 2019.
2. World Health Organization. The Health and Social Effects of Nonmedical Cannabis Use. Available at: [https://www.who.int/substance\\_abuse/publications/msbcannabis.pdf](https://www.who.int/substance_abuse/publications/msbcannabis.pdf). Accessed February 24, 2018.
3. Khanji MY, van Waardhuizen CN, Bicalho VVS, Ferket BS, Hunink MGM, Petersen SE. Lifestyle advice and interventions for cardiovascular risk reduction: a systematic review of guidelines. *Int J Cardiol* 2018;263:142-51.
4. Khanji MY, Bicalho VVS, van Waardhuizen CN, Ferket BS, Petersen SE, Hunink MGM. Cardiovascular risk assessment: a systematic review of guidelines. *Ann Intern Med* 2016;165:713-22.
5. Petersen SE, Matthews PM, Francis JM, et al. UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson* 2016;18:8.

## Performing Computed Tomography Instead of Invasive Coronary Angiography



### Sex Effects in Patients With Suspected CAD

Around 50% of women die of cardiovascular diseases. Diagnostic accuracy in detecting significant coronary artery disease (CAD) differs between men and women, underlining the need for further investigation of sex-specific differences (1). In this subanalysis of the prospective CAD-Man (Coronary Artery Disease Management) trial, we evaluated if women, compared with men, benefit from undergoing computed tomography angiography (CT) instead of invasive coronary angiography (ICA) in terms of procedural complications. Events in the follow-up period were defined in the study protocol (2). The CAD-Man trial showed that CT is a safe and accurate gatekeeper to

ICA. Initial CT instead of ICA reduced minor complications and the length of hospitalization, while increasing the diagnostic yield of ICA.

Patients with suspected CAD based on atypical chest pain and a clinical indication for ICA were randomly assigned to CT or ICA (2). Major procedural complications (death, stroke, myocardial infarction, and other complications prolonging hospitalization by at least 24 h) and minor procedural complications (e.g., groin hematoma, groin pain, infection, allergy, thrombosis, and arteriovenous fistula), defined as occurring within 48 h of the last related procedure, were compared between men and women.

The sex analysis was a planned secondary analysis (2). The chi-square test was used to evaluate minor and major procedural complications. Additionally, a post hoc power calculation was performed. The calculations were performed by nQuery release 7 (Statistical Solutions Ltd., Boston, Massachusetts). Assuming the observed overall complication rate of 7.3% and the sample size of the study, differences in complication rates of 8% (i.e., 3.3% vs. 11.3%) or larger could have been detected (power 80%, type I error = 0.05; 2-sided).

Procedural complications occurred less often in women in the CT group compared with the ICA group (CT: 1.1% vs. ICA: 11.5%). Procedural complications were similar in men in both groups (CT: 7.6% vs. ICA: 9.5%). Major procedural complications were uncommon in the CT and ICA group in both sexes (Table 1). Minor procedural complications occurred less often in women in the CT group compared with the ICA group (Table 1). The interaction sex study arm regarding procedural complication was  $p = 0.072$ .

The number of any events at long-term follow-up at 3.3 years was similar in women and men in both groups (Table 1).

This study is limited by its single-center design and the small total number of adverse events. Although earlier studies revealed differences between women and men regarding the prevalence and symptoms of CAD, ours is the first study analyzing sex differences in terms of outcomes of diagnostic procedures (CT and ICA). This study shows that women with atypical chest pain and a clinical indication for coronary evaluation may benefit from a strategy based on CT instead of ICA, specifically due to a reduction in minor procedural complications.

Possible reasons for these results are:

1. Having a lower pretest probability of disease than men and a lower rate of complex diseases women are expected to benefit less from initial ICA.
2. Women with obstructive CAD have more comorbidities, present with atypical symptoms, and tend